Back Hepatitis C

Hepatitis C

Samatasvir + Simeprevir for Hepatitis C Shows High Early Cure Rate

An interferon-free regimen containing Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX719) plus the recently approved HCV protease inhibitor simeprevir (Olysio) and ribavirin demonstrated an 85% sustained response rate at 4 weeks post-treatment in the Phase 2 HELIX-1 trial, according to a company announcement.

alt

AbbVie All-oral Combination Cures Most Hepatitis C Patients in Phase 2 Study

An all-oral regimen of AbbVie's experimental HCV drugs ABT-450, ABT-333, and ABT-367 plus ribavirin was well-tolerated and cured 88% of genotype 1 hepatitis C patients with only 8 weeks of therapy, rising to 95% with 12 weeks, according to a report in the January 16, 2014, New England Journal of Medicine.

alt

Happy Holidays from HIVandHepatitis.com

alt

Daclatasvir + Sofosbuvir Shows High Hep C Cure Rate, New Studies Underway

A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of Medicine. A series of new studies of this combination in difficult-to-treat groups including HIV/HCV coinfected people and liver transplant recipients are underway.

alt

Coffee and Tea May Help Reduce Liver Inflammation in People with Hepatitis C

Chronic hepatitis C patients who drink caffeinated filtered coffee on a daily basis were more likely to have lower alanine aminotransferase (ALT) levels, indicating less liver inflammation, according to a study published in the December 11, 2013, edition of PLoS ONE. Black or oolong tea also appeared to have a beneficial effect.

alt

Hepatitis C Prevalence Varies Widely among U.S. Latino Populations

Hepatitis C occurs at different rates in different Latino and Hispanic groups in the U.S., being highest among Puerto Rican men (nearly 12%) and lowest among South American men (0.4%), according to a report in the January 13, 2014, advance edition of the Journal of Infectious Diseases.

alt

AASLD 2013: HCV Levels in Semen May Correspond to Blood Viral Load

HIV positive men with higher hepatitis C virus (HCV) RNA levels in their blood during acute infection were more likely to have HCV in their semen as well, which may raise the risk of sexual transmission, researchers reported last month at the 64thAASLD Liver Meeting in Washington, DC.

alt

Daclatasvir + VX-135 May Cure 80% of Genotype 1 Hepatitis C Patients

An all-oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) NS4A inhibitor daclatasvir plus Vertex's experimental nucleotide polymerase inhibitor VX-135 -- without interferon or ribavirin -- produced early sustained virological response at 4 weeks post-treatment in 83% of previously untreated genotype 1 patients in a small study, Vertex announced this week.

alt

AbbVie Combo Cures 96% of Treatment-experienced Hepatitis C Patients

A 4-drug regimen containing 3 AbbVie direct-acting antivirals plus ribavirin produced sustained virological response in 96% of chronic hepatitis C patients without cirrhosis who were previously treated unsuccessfully with pegylated interferon and ribavirin, with similar response rates for HCV genotypes 1a and 1b, the company announced.

alt